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Little information is available about the long-term out-
come of renal transplantation in patients with sys-
temic vasculitis (SV). We compared the outcomes of
19 renal transplant recipients with SV with those of
38 controls matched for time of transplantation, age,
gender and source of donor. The mean post-transplant
follow-up was 58 ± 57 months for vasculitic patients
and 61 ± 49 months for controls. The actuarial 10-year
patient survival was 87% in vasculitic patients and 90%
in controls, death-censored graft survival were 84%
and 100%, respectively. The risks of acute and chronic
rejection, and arterial hypertension were not signifi-
cantly different between the two groups. Infection was
significantly more frequent in vasculitic patients (74%
vs. 34%; p = 0.01). Seven patients (36.8%) had a re-
currence of vasculitis in mean 45 months after renal
transplant (0.076/patients/year). After recurrence, one
patient had an irreversible humoral rejection, another
died from hemophagocytosis and another restarted
dialysis 1 year later. Long-term patient and renal al-
lograft survival in vasculitic patients was good. Al-
though graft function recovered in most relapsers af-
ter reinforcement of immunosuppression, one patient
died and two lost graft function.
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Introduction
A number of case reports or small-sized studies have re-
ported the outcome (1–10) and only a few studies the
long-term outcome (3,11,12) of renal transplant recipients
with systemic vasculitis (SV). The UNOS registry reported
a 3-year graft survival rate of 78% for deceased donor
transplants and 84% for living donor transplants in 114
renal transplant recipients with Wegener granulomatosis
(13). These data are similar to the 70% graft survival at 3
years reported by the ERA-EDTA registry on 115 patients
(14). The Collaborative Transplant Study (15) reported in
the form of an abstract a 10-year patient survival of 80%
and a graft survival of 65% for renal transplant recipients
with Wegener granulomatosis. However, these registries
did not provide any information about the complications,
the rate of relapses of the original disease and the causes
of death or graft failure. Only few data are available on
post-transplant polyangiitis (6,11).
The aims of this single-center analysis were (i) to com-
pare the long-term patient and renal allograft survival of
patients transplanted because of SV with those of well-
matched controls, (ii) to compare the long-term complica-
tions in these two groups of patients and (iii) to assess




Adults (>18 years) with SV who received a kidney transplantation at Os-
pedale Maggiore of Milan between December 1987, when the first renal
transplant in a patient with SV was performed, and January 2006 were
admitted to the study. The diagnosis of SV had to match the ‘Chapel Hill
Consensus Conference’ on SV (16). The diagnosis of SV was based on clin-
ical and serological criteria as well as on renal biopsy. All SV patients were
Caucasian.
Renal allograft recipients transplanted immediately before and after SV pa-
tients, matched for age (±5 years), gender and source of the donor (de-
ceased or living) were considered as controls. None of the 38 control pa-
tients showed any clinical or lab signs of SV. Seven patients were carriers
of autosomal dominant polycystic kidney disease, 6 had congenital urinary
tract abnormalities, 15 had biopsy-proven glomerulonephritis (IgA nephropa-
thy 13 patients, membranoproliferative glomerulonephritis 1, lupus nephri-
tis 1), 2 had hypertensive nephrosclerosis, 2 had chronic pyelonephritis, 1
post-partum bilateral cortical necrosis and 4 patients had renal failure of
unknown origin. All controls were Caucasian.
Definitions
Acute rejection was diagnosed on the basis of a double-checked increase
of 20% or more in plasma creatinine over the baseline, not explained by
causes other than rejection and confirmed by the response to anti-rejection
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therapy. Proteinuria of more than 0.5 g/day, and/or persistent hematuria or
cellular casts at the urinary sediment gave weight to the diagnosis. In 75%
of the cases, rejecting patients received a graft biopsy that confirmed the di-
agnosis. Renal biopsies were evaluated by light microscopy and immunoflu-
orescence. Electron microscopy was performed in doubtful cases. For the
aims of this study the severity of rejection and the classification of chronic
histological lesions were scored retrospectively according to the recently
revised Banff classification (17). Unspecific sclerosing lesions were defined
by the presence of interstitial fibrosis with tubular atrophy, glomerular and
arteriolar sclerosis, without evidence of any specific etiology. Chronic rejec-
tion was defined by the presence of chronic allograft artheriopathy and/or
chronic transplant glomerulopathy.
Acute cellular rejections were treated with intravenous methylprednisolone
pulse therapy; acute vascular rejections were treated with anti-thymocyte
globulins.
Anti-neuthrophil cytoplasmic antibodies (ANCA) were detected by enzyme-
linked immunoassays (ELISA) for antibodies against myeloperoxidase
(MPO) and proteinase 3 (PR3).
Immunosuppression
Fifteen out of 19 (79%) grafts in SV group and 30 out
of 38 (79%) in the control group were initially treated
with a triple therapy (cyclosporine or tacrolimus
plus azathioprine or mycophenolate mofetil plus
steroids). No vasculitic patients were treated with
cyclosporine plus steroids alone but three (8%)
controls were. Two (5%) controls but no SV pa-
tients were treated with tacrolimus and steroids.
Four SV patients and three controls (16% vs. 8%)
were treated with sirolimus plus cyclosporine and
steroids.
Statistical analysis
The statistical package S-Plus was used to analyze sample data. Means
± SDs were used for descriptive analysis. The t-test and the nonparamet-
ric Wilcoxon-test were used to investigate differences between the two
groups of patients. Cross-tabulated data were analyzed by chi-square test,
or by Fisher’s test when the expected cell count was less than five. Survival
Table 1: Demographic and laboratory characteristics of systemic vasculitis and controls recipients at renal transplantation
Systemic vasculitis Controls
(19 patients) (38 patients) p
Age (years) at transplant (mean ± SD) 46.6 ± 12.7 47.7 ± 6.7 ns
Sex (male/female) 13/6 26/12 ns
Living/deceased donors 14/5 28/10 ns
Months between diagnosis of renal disease and ESRD (mean ± SD) 41.8 ± 71.7 126 ± 105 0.002
Length of dialysis, months (mean ± SD) 64 ± 37 51.5 ± 43.5 ns
CAPD/HD 2/17 11/27 ns
HCV positive/negative 2/17 5/31 ns
Follow-up post-transplant months (mean ± SD) 58 ± 57 61 ± 49 ns
HLA mismatches (number) 2.7 ± 1.25 3.7 ± 0.5 ns
Panel reactive antibodies (N◦positive) 2 4 ns
CAPD = continuous ambulatory peritoneal dialysis; HD = hemodialysis; ESRD = end stage renal disease.
curves were drawn using the Kaplan–Meier estimate and compared using
the log-rank test.
Results
Of the 1225 renal transplants performed in our Hospital
between December 1987 and January 2006, 19 first trans-
plants (1.5%) were performed in patients with SV. Of them,
15 (79%) had been submitted to renal biopsy before trans-
plantation. In the other 4 patients, the diagnosis of SV was
based on clinical symptoms and signs as well as biochem-
ical and urine analysis. On the basis of clinical signs and
symptoms as well as on ANCA PR3 or MPO patterns, We-
gener granulomatosis was diagnosed in 10 patients and
microscopic polyangiitis (MPA) in 9 patients. SV was diag-
nosed 97.2 ± 44.1 months (range 55–234) before trans-
plant. The diagnosis of nephritis was made 92.2 ± 38.2
months (range 55–178) before transplantation; in 9 patients
the duration of renal disease before entering dialysis was
less than 1 year.
During dialysis, SV activity quenched in 12 patients, while
extra-renal activity persisted or relapsed in 7 patients re-
quiring new courses of steroids. At the time of renal trans-
plantation, all SV patients showed clinical quiescence for
at least 6 months.
The demographic characteristics of SV patients as well as
the number of HLA mismatches and the levels of panel-
reactive antibodies (PRA) revealed no differences from
those of the 38 controls. (Table 1). In both groups, 26%
of patients received a kidney from living related donors.
Patient and renal graft survival
The mean follow-up after renal transplantation was com-
parable in vasculitic patients and in controls (58 ± 57 and
61 ± 49 months, respectively). The actuarial 10-year pa-
tient survival was 87% in SV patients and 90% in controls
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Figure 1: Kaplan–Meier estimates of patient survival in renal
transplanted patients with systemic vasculitis (dashed line)
and in controls (solid line).
(p = ns) (Figure 1). Two out of 19 vasculitic patients (10%)
died, from lung cancer and hemophagocytic syndrome, 26
and 8 months, respectively, after renal transplant. In the
control group 2 patients died (5%), from myocardial infarc-
tion and cerebral hemorrhage, 86 and 186 months, respec-
tively, after renal transplant.
Two patients with SV lost their graft because of acute
vascular rejection and chronic rejection 6 and 52 months,
respectively, after renal transplant. Three graft failures oc-
curred in the control group 131, 148 and 154 months, re-
spectively, after renal transplant, all due to chronic rejec-
tion.
The actuarial 10-year graft survival rate censored by death
was 84% in vasculitic patients versus 100% in the control
group (p = ns) (Figure 2). After 10 years of follow-up, the
graft survival rate maintained unchanged in SV patients,
while in controls it progressively decreased to 40% at 154
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Figure 2: Kaplan–Meier estimates of renal survival probabil-
ity censored for death in renal transplanted patients with sys-
temic vasculitis (dashed line) and in controls (solid line).
Table 2: Main complications after kidney transplantation
Vasculitic Control
patients patients p
Delayed graft function >3 days 1 4 ns
Acute rejections 5 (26%) 11 (29%) ns
-Vascular rejections 1 1
- Cellular rejections 3 7
- Clinical acute rejections 1 3
Chronic rejection 2 2 ns
Unspecific sclerosing lesions 4 7 ns
Arterial hypertension 19 (100%) 37 (97%) ns
Infections n◦ of patients 14 (74%) 13 (34%) 0.01
very low. However, no significant difference between the
two curves was found.
Post-transplant complications (Table 2)
Delayed graft function occurred in one vasculitic patient
and in four controls.
Acute rejection was diagnosed in 5 out of 19 grafts in SV pa-
tients (26%). Graft biopsy was performed in four patients
and showed one vascular rejection (Banff IIB) and three
cellular rejections (Banff IA: two patients, IB one patient).
Another rejection was diagnosed on clinical grounds. The
vascular rejection was irreversible; the cellular rejections
completely recovered after therapy. Eleven acute rejec-
tions occurred in the control group (29%). Graft biopsy was
performed in eight cases and showed one vascular rejec-
tion (Banff IIA) and seven cellular rejections (Banff IA five
patients, IB two patients). In three patients the diagnosis
was made on clinical grounds. The vascular rejection and
a cellular rejection IB were partially reversible, while all the
other rejections completely recovered after therapy.
During the follow-up, two patients with SV and two con-
trols developed a biopsy-proven chronic rejection. Unspe-
cific sclerosing lesions were documented at graft biopsy
in four SV patients and in seven controls.
Looking only at patients with functioning graft at the end
of the follow-up (15 of 19), the mean levels of serum cre-
atinine and proteinuria were 1.7 ± 1.7 mg/dL and 0.35 ±
0.08 mg/dL, respectively, in patients with SV.
A higher number of SV patients developed severe infec-
tions requiring hospitalization in comparison to controls
(14/19 vs. 13/ 38; p = 0.01). The types of infection are
reported in Table 3.
Outcome of SV during renal transplantation (Table 4)
Seven patients (36.8%) showed a recurrence of vasculitis
(MPA five patients, Wegener granulomatosis two patients)
in mean 45 months after renal transplantation (range 0.5–
192) with a relapse rate of 0.076/patient/year. The relapse
was clinically characterized by proteinuria with microscopic
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Table 3: Severe infections requiring hospitalization in transplanted
patients with systemic vasculitis and in the control group
Systemic vasculitis Control patients
patients (19) (38)
Number of infections Number of infections
Pneumonia 3 1
Herpes zoster 1 5
CMV infections 2 4
Urinary infections 6 4
EBV infections 1 0
Other infections 4∗ 2∗∗
Total 14 patients 13 patients
(17 episodes) (16 episodes)
∗Acute gastroenteritis = two patients; cutaneous abscess = one
patient; BK virus infection = one patient.
∗∗Cutaneous abscess = two patients.
hematuria in all cases and by an increase in serum creati-
nine in six out of seven patients. Lung hemorrhage de-
veloped in two patients, associated with cutaneous vas-
cultis in one of the two patients. Histologically, all patients
showed a pauci-immune necrotizing glomerulonephritis. At
the time of recurrence, all but two patients had positive
ANCA.
Four out of the 7 recurrent patients (numbers 1–4) de-
veloped recurrence of vasculitis 0.5–3 months after renal
transplantation and all of them developed an acute rejec-
tion during the first year after renal transplant. Three of
them (patients 1,2,4) had had a rapidly progressive renal
insufficiency leading to dialysis.
The other three patients developed a recurrence of necro-
tizing glomerulonephritis 3 to 16 years after renal transplan-
tation. The recurrence was characterized in all cases by an
increase of serum creatinine, proteinuria and hematuria
There was no significant difference between the seven
patients with recurrence and the other 12 SV patients as
far as sex, age, duration of renal disease before dialysis,
duration of dialysis, episodes of recurrence during dialy-
Table 4: Patients with recurrence of systemic vasculitis
At recurrence Outcome after therapy At last observation
Time of ANCA at S.creat from- U.prot Ery S.creat U.prot Ery Follow-up S.creat U.prot
Pts Sex Age recurrence flare to mg/dL g/24h hpf Therapy mg/dL g/24h hpf after Tx mg/dL g/24h
1 M 59 1 month Neg 3.3 → 6 4 3+ MP 3 Cycloph 1.8 0.2 0 43 1.8 0.2
2 M 31 0.5 month PR3 pos 2 → 3.5 0.7 3+ MP 3 1.5 0.24 1+ 8 2 0.5
3 M 48 3 months Neg 1.8 → 1.8 3.1 3+ MP3 Cycloph 1.5 5.7 1+ 6 6 ESRD 5.9
4 I◦ M 51 2 months MPO pos 1.6 → 2.5 1.3 3+ MP 3 1.4 0.14 0
4 II◦ M 57 65 months MPO pos 1.8 → 2.6 2.8 2+ Cycloph 1.79 1.5 1+ 66 1.8 0.9
5 F 54 37 months MPO pos 1.7 → 5.4 3.9 3+ MP 3 Cycloph 2.1 1.3 2+ 52 5.9 ESRD 1.45
6 M 40 78 months MPO pos 1 → 1.5 1.4 3+ MP 3 Cycloph 1 0.06 0 95 1.0 0.09
7 F 48 192 months PR3 pos 2 → 3.4 1.9 2+ MP 3 Cycloph 2.7 0.9 0 200 2.7 0.9
Pts = patients; ANCA = anti-neuthrophil cytoplasmic antibodies; s.crea = serum creatinine; U.prot = proteinuria; Ery = Erythrocyte; hpf
= high power field; MP = methylprednisolone pulses; Tx = transplant; MPO= myeloperoxidase; PR3 = proteinase 3; neg = negative;
pos = positive.
sis, type of ANCA, source of kidney (deceased, living) or
type of post-transplant immunosuppression. The only sig-
nificant difference was a higher number of acute rejections
in patients with recurrence than in nonrecurrent patients (p
= 0.04) (Table 5).
All the seven patients with recurrence were treated with
three methylprednisolone (MP) pulses (500 mg/day each)
followed by oral prednisone 0.5 mg/kg/day associated with
oral cyclophosphamide 2 mg/kg/day for 2–12 months in
five of them. During cyclophosphamide therapy all the
other anti-rejection immunosuppression therapies were
withdrawn in three patients (numbers 1,3,6). In the other
two patients, mycophenolate mofetil (patient 5) and aza-
thioprine (patient 7) were withdrawn, while tacrolimus (pa-
tient 5) and cyclosporine (patient 7) were continued un-
changed.
Patient 4 had a second relapse of vasculitis 5 years
later with an increase in serum creatinine and protein-
uria. Mycophenolate mofetil was stopped and replaced
by cyclophosphamide for 6 months while tacrolimus and
steroids were continued.
In three patients (1,4,6) serum creatinine returned to the
pre-recurrence levels. At last observation, 43, 66 and 95
months, respectively, after renal transplant all these three
patients had stable renal function with normal urinalysis in
patients 1 and 6 and mild proteinuria in patient 4. In pa-
tient 5, the episode of recurrence was well controlled with
MP pulses and cyclophosphamide, but 1 year later serum
creatinine progressively increased without any clinical or
laboratory signs of recurrence of vasculitis. Renal biopsy
allowed the diagnosis of chronic rejection without any sign
of vasculitis. The patient had to restart dialysis 52 months
after renal transplant. Patient 7 was treated with a course
of MP pulses and cyclophosphamide. Serum creatinine and
proteinuria improved. Six months later, when a control re-
nal biopsy demonstrated interstitial fibrosis without signs
of vasculitis, cyclophosphamide was withdrawn. At the last
observation, 1 year after SV recurrence, serum creatinine
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Table 5: Demographic, clinical and laboratory characteristics of patients with systemic vasculitis who relapsed and whose who did not
Patients with recurrent Nonrecurrent
renal vasculitis: 7 patients 12 p
Age at tx (years) mean ± SD 53 ± 10.3 55.3 ± 11.8 ns
Sex (male/female) 5/2 8/4 ns
Months between diagnosis of vasculitis and ESRD mean ± SD 70.6 + 108.2 25 + 34.6 ns
Duration of dialysis (months) mean ± SD 49.8 ± 21.4 72.3 ± 42.1 ns
Patients with recurrence of vasculitis during dialysis N◦ (%) 1 (14%) 6 (50%) ns
Type of dialysis HD/CAPD 5/1 11/1 ns
Follow-up post-tx (months) mean ± SD 66.6 ± 67 52.4 ± 52.1 ns
Deceased/living donors 6/1 8/4 ns
HCV positivity (yes/no) 2/5 0/12 ns
Immunosuppressive therapy 1/2/3/4 1/4/2/0 2/6/0/4 ns
HLA mismatches (number) 2.4 ± 1.14 2.7 ± 1.5 ns
Panel reactive antibodies (N◦ positive) 1 1 ns
Arterial hypertension yes/no 7/0 11/1 ns
Acute rejection yes/no 4/3 1/11 0.04
Chronic rejection number 1 1 ns
Unspecific sclerosing lesions number 1 3 ns
N◦ patients with infections yes/no 6/1 8/4 ns
Final serum creat. (mg/dL) mean ± SD 2.3 ± 0.9 1.4 ± 0.4 0.02
Final proteinuria (g/24 h) mean ± SD 1.47 ± 2 0.26 ± 0.26 0.02
N◦ of deaths 1 1 ns
N◦ of lost kidney 2 0 ns
Immunosuppressive therapy 1 = steroids + cyclosporine + azathioprine; 2 = steroids + tacrolimus + mycophenolate; 3 = steroids +
cyclosporine + mycophenolate; 4 = steroids + sirolimus + cyclosporine.
was 2.7 mg/dL with mild proteinuria (0.9 g/24 h). Of the
remaining two patients, patient 2 died from hemophago-
cytic syndrome and patient 3 lost the allograft because
of humoral rejection, 8 and 6 months, respectively, after
renal transplantation. If we look at the results at the last
follow-up visit, the patients who had recurrence showed
significantly higher mean levels of serum creatinine and
proteinuria (Table 5).
Discussion
In this study we have reported our single-center experi-
ence with renal transplantation in 19 SV patients followed
in mean for 58 months, one of the longest follow-ups re-
ported up until now. All patients were Caucasian and all
were treated with calcineurin inhibitors after transplanta-
tion. We used as controls those patients who were trans-
planted immediately before and after those with SV and
matched with them for many of the variables, which might
influence the outcome of renal transplant recipients. The
actuarial 10-year patient and pure graft survival were, 87%
and 84%, respectively, in SV patients, and 90% and 100%
in the control group. A limitation of this study is represented
by the small number of patients. Our data seem to suggest
that good results can be obtained, even in the long-term,
with renal transplantation in SV patients, although a lower
survival rate has been observed at 5 and 10 years for vas-
culitic patients when compared to controls.
The number of rejections, the risk of developing late allo-
graft failure as well as the prevalence of arterial hyperten-
sion were not different between SV patients and controls.
In contrast vasculitic patients had a significantly higher
number of infections requiring hospitalization than con-
trols. There is only one other paper reporting the frequency
of these complications in 20 transplant patients with vas-
culitis (4). In that paper no difference in the rates of rejec-
tion and infection was found between vasculitic patients
and the total population transplanted in the same institu-
tion. No other data are available regarding these complica-
tions in the published studies.
The risk of recurrence of SV after renal transplantation is a
controversial issue. The relapse rate after renal transplant is
lower than that observed before and during dialysis (12,18).
However, the rate of post-transplant vasculitic recurrences
and the impact on patient and graft survival are not clearly
defined. Nachman et al. (5), in 28 patients (7%) followed
for 56 months, reported two recurrences, with graft fail-
ure in one of them. The same investigators reported the
results of a pooled analysis on 127 renal transplant recip-
ients with SV; recurrence occurred in 22 patients (17%)
with renal involvement in 12 of them. Of the 16 patients
for whom information about the outcome was available, 11
went into stable remission after therapy, 2 relapses led to
graft loss, 1 patient lost the graft in spite of the remission of
the vasculitic flare and 1 patient died as a consequence of
the relapse. Nyberg et al. (3) reported 6 renal recurrences
in 17 patients submitted to 22 renal transplants (27%),
in 2 cases the graft was lost due to renal relapse. Also
the number of relapses per patient per year varied signif-
icantly being 0.02 patient/year (12), 0.06 patient/year (19)
and 0.10 patient/year (4), respectively, in three different
studies.
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Seven out of 19 patients followed in our Unit for a mean
period of 5 years after renal transplantation developed a
recurrence of vasculitis, which means an incidence of re-
lapses of 0.076/patient/year. In all cases, the recurrences
were characterized by biopsy proven pauci-immune necro-
tizing glomerulonephritis associated in two cases with lung
involvement. Microscopic hematuria and proteinuria were
the heralding signs for all the renal recurrences.
We could not find any significant difference between pa-
tients who relapsed and those who did not in terms of
duration of dialysis, episodes of recurrence during dialy-
sis, type of ANCA, deceased or living transplant or type
of immunosuppressive therapy after renal transplant. The
only significant difference between the two groups was
a higher incidence of acute rejection during the first year
after transplant in those patients who had a relapse. Al-
though the relapses occurred in mean 45 months after re-
nal transplantation, in 4 out of the 7 patients the recurrence
occurred within 3 months after transplantation.
After MP pulses and cyclophosphamide, all our patients re-
covered renal function, but one patient died of hemophago-
cytosis. The pathogenesis of this syndrome is still unclear.
However, the strict link between systemic inflammation
and hemophagocytosis, coupled with peripheral T-cell ex-
pansion and deficient natural killer activity often found in pa-
tients with this syndrome (20) supports the hypothesis of a
dysregulation in the inflammatory and immune response.
It is possible to speculate that the combination of inflam-
mation during recurrence with the immune dysregulation
caused by treatment may have contributed to the develop-
ment of this rare syndrome in our patient.
Two other patients lost their graft function because of acute
vascular and chronic rejection, respectively, and another
patient showed a progressive increase in serum creatinine.
At the last follow-up, the mean levels of serum creatinine
and proteinuria were more elevated in patients with recur-
rence than in the other vasculitic patients. Thus, in spite of a
good early response to therapy it appears that recurrence
of vasculitis eventually may have an unfavorable impact
on renal allograft function in at least half of the patients.
Whether recurrence should be considered as a marker or
a trigger of a high immunological response is still a matter
of speculation.
In conclusion, our results, although based on a small sam-
ple size, underline that transplanted vasculitic subjects may
have good patient and graft survival rates at 10 years, al-
though infections were more frequent in vasculitic patients
than in controls. Therefore, patients with SV may be con-
sidered as suitable candidates for kidney transplantation.
However, the risk of recurrence is not infrequent and can
have severe consequences, implying the need of continu-
ous and careful surveillance to promptly diagnose and treat
such complication. We suggest checking for ANCA every
6–12 months, bearing in mind that negative results do not
rule out completely the possibility of SV relapse. As an in-
crease in urine protein/creatinine ratio and/or the onset of
hematuria and cylindruria in the urine sediment may sug-
gest a relapse of SV, we suggest to monitor urinalysis every
month during the first year after transplantation and every
3 months during the follow-up. The final diagnosis may re-
quire graft biopsy.
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